ClinicalTrials.gg
Not yet recruitingNCT06758739Updated Mar 6, 2025

Comparison of Curcumin and Intralesional Steroids in Oral Submucous Fibrosis

A Phase 3 interventional study of Curcumin (Turmeric) and Intralesional Steroid Injection in Oral Submucous Fibrosis, sponsored by Services Institute of Medical Sciences, Pakistan. Not yet recruiting at 1 site in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by Services Institute of Medical Sciences, Pakistan · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if Curcumin is better than Intralesional Steroid Injection for the treatment of oral submucous fibrosis. The main question it aims to answers are:

  1. If Curcumin is more effective to improve burning sensation as compared to Intralesional steroid.
  2. Does Curcumin treatment results in better mouth opening versus Intralesional steroid.
  3. Can Curcumin helps to improve tongue protrusion as compared to Intralesional steroids.

Participants will be:

  • Assessed for one month, two month and three month.
  • Burning Sensation will be assessed with visual analogue scale (VAS).
  • Mouth Opening will be measured in mm with ruler.
  • Tongue Protrusion will be assessed with the visual analogue scale (VAS).
Read the detailed description

Objective:

To compare the efficacy of Curcumin versus Intralesional steroids in term of burning sensation, mouth opening and tongue Protrusion

Hypothesis:

Curcumin is more effective in terms of burning sensation, mouth opening (interincisal distance) and tongue Protrusion as compared to intralesional steroids.

Operational Definitions:

Oral submucous fibrosis is chronic, slowly progressive precancerous condition caused by areca nut characterized by restricted mouth opening, burning sensation, stiffness and blanching of mucosa and limitation of tongue Protrusion9. It will be clinically assessed as difficulty in mouth opening, burning sensation, fibrous bands \& blanching of mucosa along with limited tongue movement.

Efficacy:

Efficacy of Curcumin \& intralesional steroids will be assessed in terms of burning sensation VAS score, mouth opening \& Tongue Protrusion

Burning Sensation:

A burning sensation in oral submucous fibrosis is often due to tissue changes, dryness, nutritional deficiencies, or secondary infections affecting the oral mucosa. Patient feels pain or discomfort in mouth especially when eating hot or spicy food Patient will be asked for burning sensation \& based on severity numerical score given by VAS (Visual Analog Scale) (Bohra et al.)9

Mouth Opening:

Mouth opening is progressively restricted due to fibroses and stiffness of oral tissue. It will be measured in mm. Patient will be asked to open mouth as wide as he/she can \& with the help of mental scale \& divider (Vernier caliper) between maxillary incisor \& mandibular incisor9.

Tongue Protrusion:

Tongue Protrusion in oral submucous fibrosis refers to the difficulty or inability to fully move the tongue out of the mouth due to stiffness and restricted mobility caused by fibrotic changes in the oral tissues. It will be assessed from normal mesio-incisal angel of maxillary central incisor to the tip of tongue when maximally extended with wide mouth open (Ramesh et al.)11

Material and Methods:

Study Design:

Randomized Central trial (RCT)

Study Setting:

Department of Oral \& Maxillofacial surgery, Services Institute of Medical Sciences Lahore

Duration of Study:

Six months

Sample Size: A sample size will be of 70 patients (35 in each group). Calculated using the expected mean difference of burning sensation VAS score between curcumin group and intralesional steroids inj.

Sampling Technique:

Non-probability purposive sampling technique.

Sample Selection:

Inclusion Criteria:

Patients diagnosed with Oral submucous fibrosis in accordance with operational definition.

Male \& Female

Exclusion Criteria:

Patient unable to quit the habit of gutkha, tobacco \& betel nut chewing Patient With uncontrolled diabetes Patient with chronic kidney disease Pregnant female Patient with untreated malignancy/taking immunosuppressant drugs Patient with H/O ORAL SUBMUCOUS FIBROSIS in last months

Data Collection Procedure:

All eligible patients undergoing oral submucous fibrosis treatment will be invited to participate in the study and informed consent will be obtained from all the volunteer participants. Total 70 (35 in each group) will be randomized into two equal size groups i.e. Group A and B by using online computer-generated program which concealed randomization and treatment allocation. A structured Proforma will be used to call demographic and clinical data. Before treatment, baseline burning sensation, mouth opening (interincisal distance) and tongue Protrusion will be noted. In group A, Patient will receive Curcumin Capsule (nutrifactor) 2 per day for 3 months. In group B, Patient will receive intralesional steroid injection 4mg/1cc weekly for 3 months. Participants health care provider, data collector and outcome assessors will be blinded to the treatment allocation. Patient will be assessed for burning sensation, INTERINCISAL DISTANCE \& tongue protrusion monthly. As per operational definitions, efficacy in terms of burning sensation VAS score, greater inter Incisal distance \& tongue Protrusion will be compared between Curcumin and Intralesional steroid groups.

Data Collection Tools:

All Study variables will be assessed by single person at Month 1, Month 2 and Month 3 post clinical trial. Clinical parameters will be assessed through proforma designed in English as well as in Local language.

Data Analysis Procedure:

Statistical Package for Social Sciences (SPSS) version 27 will be used for data entry \& analysis. The quantitative variables such as age, burning sensation VAS score, mouth opening \& tongue Protrusion, will reported using mean ± standard deviation. The quantitative variable such as gender will be reported using percent. The baseline profile between groups will be compared using student t-test. The improvement within the group by the end of 1st, 2nd \& 3rd month will be tabulated \& analyzed. The clinical improvement of a particular regimen (within the same group) before \& after treatment will be analyzed using paired t-test. The improvement observed serially within the same group will be evaluated using repeated measures ANOVA. Comparisons between the two groups will be done using unpaired t-test.

02

Conditions studied

  • Oral Submucous Fibrosis

Keywords

  • Potentially Malignant Disorder
  • Oral Submucous Fibrosis
  • Intralesional Steroids
  • Curcumin
  • Anti-Inflammatory
  • Anti-Fibrotic
03

In context

Lead sponsor

Services Institute of Medical Sciences, Pakistan is the lead sponsor of 34 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with Oral submucous fibrosis in accordance with operational definition.
  • Male \& Female

Exclusion criteria

Exclusion Criteria:

  • Patient unable to quit the habit of gutkha, tobacco \& betel nut chewing
  • Patient With uncontrolled diabetes
  • Patient with chronic kidney disease
  • Pregnant female
  • Patient with untreated /taking drugs
  • Patient with H/O ORAL SUBMUCOUS FIBROSIS in last months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Group A

    The Group A will undergo curcumin treatment for oral submucous Fibrosis. In Group A curcumin capsule (500 mg) will be given two per day. Patient will receive 1000 mg curcumin per day and will be assessed month on month basis for three months.

    Drug: Curcumin (Turmeric)

  • Experimental
    Group B

    The Group B will undergo Intralesional Steroids treatment in oral submucous fibrosis. In Group B Intralesional Steroid Injection will be administered weekly and assessed on monthly basis for three months.

    Drug: Intralesional Steroid Injection

Interventions

  • DrugCurcuminStudies of CurcuminCurcumin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Curcumin Capsule will be given two per day for three months. Patient Recovery progress will be monitored month on month basis for consecutive three month.

  • DrugIntralesional Steroid Injection

    Intralesional Steroid Injection (1cc), one per week, will be administered in the fibrous bands wherever formed in the oral cavity. Patient recovery progress will be monitored on monthly basis for three months.

06

What researchers measure

Primary outcomes

  1. Mean of Burning Sensation

    A burning sensation in oral submucous fibrosis is often due to tissue changes, dryness, nutritional deficiencies, or secondary infections affecting the oral mucosa. Patient will be asked for burning sensation \& based on severity numerical score given by VAS (Visual Analog Scale) 0-100.

    Time frame: Monthl 1, Month 2, Month 3

  2. Mean of Mouth Opening

    Mouth opening is progressively restricted due to fibroses and stiffness of oral tissue. It will be measured in mm. Patient will be asked to open mouth as wide as he/she can \& with the help of metal scale \& divider (Vernier caliper) between maxillary incisor \& mandibular incisor.

    Time frame: Month 1, Month 2, Month 3

  3. Mean of Tongue Protrusion

    Tongue Protrusion in oral submucous fibrosis refers to the difficulty or inability to fully move the tongue out of the mouth. It will be assessed from normal mesio-incisal angel of maxillary central incisor to the tip of tongue when maximally extended with wide mouth open by Visual Analogue Scale (VAS) 0-100.

    Time frame: Month 1, Month 2, Month 3

07

Study locations

1 site
08

References and documents

Publications

  • Kerr AR, Warnakulasuriya S, Mighell AJ, Dietrich T, Nasser M, Rimal J, Jalil A, Bornstein MM, Nagao T, Fortune F, Hazarey VH, Reichart PA, Silverman S, Johnson NW. A systematic review of medical interventions for oral submucous fibrosis and future research opportunities. Oral Dis. 2011 Apr;17 Suppl 1:42-57. doi: 10.1111/j.1601-0825.2011.01791.x. PubMed 21382138 ↗
  • Roques C, Teot L. The use of corticosteroids to treat keloids: a review. Int J Low Extrem Wounds. 2008 Sep;7(3):137-45. doi: 10.1177/1534734608320786. Epub 2008 Jul 8. PubMed 18611924 ↗
  • Ramesh, D.N.S.V., Saba N. lycopene and combination of lycopene with multivitamins in the treatment of oral submucous fibrosis patients - A comparative study. Int. J Curr Res. 2017;9:53177-82.
  • Piyush P, Mahajan A, Singh K, Ghosh S, Gupta S. Comparison of therapeutic response of lycopene and curcumin in oral submucous fibrosis: A randomized controlled trial. Oral Dis. 2019 Jan;25(1):73-79. doi: 10.1111/odi.12947. Epub 2018 Aug 22. PubMed 30059188 ↗
  • Bohra A, Maheswari TNU, Harsh A, Garg A. Black Turmeric and Aloe Vera in the Management of Oral Submucous Fibrosis: A Prospective Clinical Study. Asian Pac J Cancer Prev. 2021 Dec 1;22(12):3941-3947. doi: 10.31557/APJCP.2021.22.12.3941. PubMed 34967575 ↗
  • Yadav M, Aravinda K, Saxena VS, Srinivas K, Ratnakar P, Gupta J, Sachdev AS, Shivhare P. Comparison of curcumin with intralesional steroid injections in Oral Submucous Fibrosis - A randomized, open-label interventional study. J Oral Biol Craniofac Res. 2014 Sep-Dec;4(3):169-73. doi: 10.1016/j.jobcr.2014.11.003. Epub 2014 Nov 20. PubMed 25737939 ↗
  • Nagpal M, Sood S. Role of curcumin in systemic and oral health: An overview. J Nat Sci Biol Med. 2013 Jan;4(1):3-7. doi: 10.4103/0976-9668.107253. PubMed 23633828 ↗
  • Zhang SS, Gong ZJ, Li WH, Wang X, Ling TY. Antifibrotic effect of curcumin in TGF-beta 1-induced myofibroblasts from human oral mucosa. Asian Pac J Cancer Prev. 2012;13(1):289-94. doi: 10.7314/apjcp.2012.13.1.289. PubMed 22502687 ↗
  • Aziz SR. Coming to America: betel nut and oral submucous fibrosis. J Am Dent Assoc. 2010 Apr;141(4):423-8. doi: 10.14219/jada.archive.2010.0194. PubMed 20354091 ↗
  • Nigam NK, Aravinda K, Dhillon M, Gupta S, Reddy S, Srinivas Raju M. Prevalence of oral submucous fibrosis among habitual gutkha and areca nut chewers in Moradabad district. J Oral Biol Craniofac Res. 2014 Jan-Apr;4(1):8-13. doi: 10.1016/j.jobcr.2013.10.005. Epub 2013 Nov 20. PubMed 25737912 ↗
  • Rajendran R, Deepthi K, Nooh N, Anil S. alpha4beta1 integrin-dependent cell sorting dictates T-cell recruitment in oral submucous fibrosis. J Oral Maxillofac Pathol. 2011 Sep;15(3):272-7. doi: 10.4103/0973-029X.86678. PubMed 22144828 ↗
  • Pindborg JJ, Sirsat SM. Oral submucous fibrosis. Oral Surg Oral Med Oral Pathol. 1966 Dec;22(6):764-79. doi: 10.1016/0030-4220(66)90367-7. No abstract available. PubMed 5224185 ↗
  • Hazarey VK, Erlewad DM, Mundhe KA, Ughade SN. Oral submucous fibrosis: study of 1000 cases from central India. J Oral Pathol Med. 2007 Jan;36(1):12-7. doi: 10.1111/j.1600-0714.2006.00485.x. PubMed 17181736 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Sep 2025, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2024
First posted
Jan 6, 2025
StartEst.
Apr 2025
Primary completionEst.
Sep 2025
CompletionEst.
Oct 2025
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06758739
Lead sponsor
Services Institute of Medical Sciences, Pakistan
Responsible party
Hafiza Sara Adrees (Post Graduate Resident OMFS, Services Institute of Medical Sciences, Pakistan) — Principal investigator
First posted
Jan 6, 2025
Start date
Apr 2025 (estimated)
Primary completion
Sep 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
Mar 6, 2025

Study contacts

Hafiza Sara Adrees, BDS
Contact
saramidrees113@gmail.com
+92 307 3002818
Hafiz Aamer Iqbal, BDS FCPS OMFS
Contact
haafiz.amer.iqbal@gmail.com
+92 333 4955789

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion